HIF1A and metabolic dysfunction-associated steatohepatitis: These findings suggested that tipifarnib attenuated glycolytic metabolism in hepatic cancer cell lines cultured under NASH-like conditions and HIF-1α played a major role in regulating this metabolic reprogramming.